Date: 2015-10-14
Type of information: Private placement
Company: Affimed (Germany)
Investors: undisclosed existing shareholder
Amount: $21.8 million (€ 19.2 million)
Funding type: private placement
Planned used:
Others: * On October 14, 2015, Affimed , a clinicalstage biopharmaceutical company developing highly targeted cancer immunotherapies, announced that an existing shareholder has increased its position in the Company by purchasing 3.3 million shares. The Agreement was signed on Oct. 9, 2015 and will lead to an investment of $21.8 million (€ 19.2 million).
Therapeutic area: Cancer - Oncology
